Structure and function in gene patenting
- 1 February 1997
- journal article
- review article
- Published by Springer Nature in Nature Genetics
- Vol. 15 (2) , 125-130
- https://doi.org/10.1038/ng0297-125
Abstract
The United States patent system treats DNA sequences as large chemical compounds in determining their patentability. This approach has been helpful to those who seek to patent previously unidentified DNA sequences, but it may prove less advantageous from the perspective of those who elucidate biological functions and disease relevance of previously identified genes. A current controversy over patent rights for DNA sequences encoding leptin receptors provides a useful case study for illustrating some of the issues that are likely to arise in applying doctrine derived from chemical patent cases in the context of gene discovery.Keywords
This publication has 25 references indexed in Scilit:
- Leptin activation of Stat3 in the hypothalamus of wild–type and ob/ob mice but not db/db miceNature Genetics, 1996
- Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db MiceCell, 1996
- Abnormal splicing of the leptin receptor in diabetic miceNature, 1996
- Identification and expression cloning of a leptin receptor, OB-RCell, 1995
- {BLR 2122} ESTs - In re Bell - In re Deuel - Prior ArtPublished by Mary Ann Liebert Inc ,1995
- Positional cloning of the mouse obese gene and its human homologueNature, 1994
- Ledemnan to Leave FemilabScience, 1989
- Glycogen and phosphorylase in Klinefelter's syndrome: a histochemical studyCellular and Molecular Life Sciences, 1978
- Thermal Stress and Low Cycle FatigueJournal of Applied Mechanics, 1966
- Wheeler and JackBMJ, 1963